Andrew M McDonald1,2, Yanjun Chen1, Jessica Wu1, Lindsey Hageman1, Liton Francisco1, Michelle Kung1, F Lennie Wong3, Emily Ness1, Wendy Landier1,4, Kevin Battles1, Donna Salzman5, Daniel J Weisdorf6, Stephen J Forman7, Mukta Arora6, Saro H Armenian3, Smita Bhatia1,4. 1. Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL. 2. Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL. 3. Department of Population Sciences, City of Hope, Los Angeles, CA. 4. Division of Pediatric Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL. 5. Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL. 6. Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN. 7. Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Los Angeles, CA.
Abstract
PURPOSE: To examine the association between total body irradiation (TBI) and subsequent breast cancer in women treated with blood or marrow transplantation (BMT) for hematologic malignancies. PATIENTS AND METHODS: Participants were drawn from the BMT Survivor Study (BMTSS), a retrospective cohort study that included patients who underwent transplantation between 1974 and 2014 and survived for ≥ 2 years after BMT. Patients with pre-BMT chest radiation or a history of breast cancer were excluded. Participants completed the BMTSS survey, which included details regarding breast cancer diagnosis. Subsequent breast cancer was confirmed by pathology report review or physician notes. Cox proportional hazards models assessed the association between TBI and subsequent breast cancer. Standardized incidence ratios were calculated to determine the excess risk of subsequent breast cancer compared with that in the general population. RESULTS: A total of 1,464 female BMT survivors (allogeneic: n = 788; autologous: n = 676) participated, with a median follow-up of 9.3 years from BMT. TBI was used in 660 patients (46%). Thirty-seven women developed subsequent breast cancer (allogeneic: n = 19; autologous: n = 18). Multivariable analysis revealed that exposure to TBI was associated with an increased risk of subsequent breast cancer among allogeneic BMT survivors (hazard ratio [HR], 3.7 [95% CI, 1.2 to 11.8]; P = .03) and autologous BMT survivors (HR, 2.6 [95% CI, 1.0 to 6.8]; P = .048). Pre-BMT exposure to alkylating agents was associated with an increased risk of subsequent breast cancer among autologous BMT survivors (HR, 3.3 [95% CI, 1.0 to 9.0]; P = .05). Compared with that in the general population, exposure to TBI at age < 30 years was associated with a 4.4-fold higher risk of subsequent breast cancer in allogeneic BMT survivors and a 4.6-fold higher risk in autologous BMT survivors. CONCLUSION: The association between TBI and subsequent breast cancer, especially among those exposed at a young age, as well as pre-BMT exposure to alkylating agents, should inform breast cancer screening for early detection.
PURPOSE: To examine the association between total body irradiation (TBI) and subsequent breast cancer in women treated with blood or marrow transplantation (BMT) for hematologic malignancies. PATIENTS AND METHODS: Participants were drawn from the BMT Survivor Study (BMTSS), a retrospective cohort study that included patients who underwent transplantation between 1974 and 2014 and survived for ≥ 2 years after BMT. Patients with pre-BMT chest radiation or a history of breast cancer were excluded. Participants completed the BMTSS survey, which included details regarding breast cancer diagnosis. Subsequent breast cancer was confirmed by pathology report review or physician notes. Cox proportional hazards models assessed the association between TBI and subsequent breast cancer. Standardized incidence ratios were calculated to determine the excess risk of subsequent breast cancer compared with that in the general population. RESULTS: A total of 1,464 female BMT survivors (allogeneic: n = 788; autologous: n = 676) participated, with a median follow-up of 9.3 years from BMT. TBI was used in 660 patients (46%). Thirty-seven women developed subsequent breast cancer (allogeneic: n = 19; autologous: n = 18). Multivariable analysis revealed that exposure to TBI was associated with an increased risk of subsequent breast cancer among allogeneic BMT survivors (hazard ratio [HR], 3.7 [95% CI, 1.2 to 11.8]; P = .03) and autologous BMT survivors (HR, 2.6 [95% CI, 1.0 to 6.8]; P = .048). Pre-BMT exposure to alkylating agents was associated with an increased risk of subsequent breast cancer among autologous BMT survivors (HR, 3.3 [95% CI, 1.0 to 9.0]; P = .05). Compared with that in the general population, exposure to TBI at age < 30 years was associated with a 4.4-fold higher risk of subsequent breast cancer in allogeneic BMT survivors and a 4.6-fold higher risk in autologous BMT survivors. CONCLUSION: The association between TBI and subsequent breast cancer, especially among those exposed at a young age, as well as pre-BMT exposure to alkylating agents, should inform breast cancer screening for early detection.
Authors: Heidi D Nelson; Rochelle Fu; Amy Cantor; Miranda Pappas; Monica Daeges; Linda Humphrey Journal: Ann Intern Med Date: 2016-01-12 Impact factor: 25.391
Authors: Anna S Holmqvist; Yanjun Chen; Jennifer Berano Teh; Canlan Sun; Jillian M Birch; Cor van den Bos; Lisa R Diller; Kimberley Dilley; Jill Ginsberg; Laura T Martin; Rajaram Nagarajan; Paul C Nathan; Joseph P Neglia; Monica Terenziani; David Tishler; Anna T Meadows; Leslie L Robison; Odile Oberlin; Smita Bhatia Journal: Cancer Date: 2018-12-17 Impact factor: 6.860
Authors: Navneet S Majhail; Li Tao; Christopher Bredeson; Stella Davies; Jason Dehn; James L Gajewski; Theresa Hahn; Ann Jakubowski; Steven Joffe; Hillard M Lazarus; Susan K Parsons; Kim Robien; Stephanie J Lee; Karen M Kuntz Journal: Biol Blood Marrow Transplant Date: 2013-07-30 Impact factor: 5.742
Authors: Valérie D V Sankatsing; Nicolien T van Ravesteyn; Eveline A M Heijnsdijk; Caspar W N Looman; Paula A van Luijt; Jacques Fracheboud; Gerard J den Heeten; Mireille J M Broeders; Harry J de Koning Journal: Int J Cancer Date: 2017-08-15 Impact factor: 7.396
Authors: Lene H Veiga; Rochelle E Curtis; Lindsay M Morton; Diana R Withrow; Rebecca M Howell; Susan A Smith; Rita E Weathers; Kevin C Oeffinger; Chaya S Moskowitz; Tara O Henderson; Michael A Arnold; Todd M Gibson; Wendy M Leisenring; Joseph P Neglia; Lucie M Turcotte; John A Whitton; Leslie L Robison; Gregory T Armstrong; Peter D Inskip; Amy Berrington de Gonzalez Journal: JAMA Pediatr Date: 2019-12-01 Impact factor: 16.193
Authors: Renée L Mulder; Leontien C M Kremer; Melissa M Hudson; Smita Bhatia; Wendy Landier; Gill Levitt; Louis S Constine; W Hamish Wallace; Flora E van Leeuwen; Cécile M Ronckers; Tara O Henderson; Mary Dwyer; Roderick Skinner; Kevin C Oeffinger Journal: Lancet Oncol Date: 2013-12 Impact factor: 41.316
Authors: Lisa B Kenney; Yutaka Yasui; Peter D Inskip; Sue Hammond; Joseph P Neglia; Ann C Mertens; Anna T Meadows; Debra Friedman; Leslie L Robison; Lisa Diller Journal: Ann Intern Med Date: 2004-10-19 Impact factor: 51.598